Objective: The neurotrophin receptor TrkB has been implicated in the regulation of energy homeostasis in rodents. We have previously identified four rare missense mutations in the gene encoding TrkB, NTRK2, in 198 severely obese children with developmental delay. We have now undertaken a more detailed analysis of the in vitro functional consequences of the mutations identified: I98V, P660L, T821A and Y722C. Design: Wild-type and mutant TrkB receptor constructs were stably transfected into PC12 cells and the signaling responses to the endogenous ligand, brain-derived neurotrophic factor (BDNF), were examined by Western blotting of cell lysates. In the case of Y722C, PC12 cells stably expressing this mutant were studied for their ability to respond to BDNF by promoting neurite outgrowth and cell survival. Results: Further functional characterization of the previously reported Y722C TrkB mutation reveals impaired activation of mitogen-activated protein kinase, phospholipase C-g and Akt, as well as reduced BDNF-induced neurite outgrowth and cell survival in stably transfected PC12 cell lines. However, the signaling properties of I98V, P660L and T821A were all indistinguishable from wild type. Conclusion: We provide further evidence for the impairment in signaling by Y722C and show that as well as a loss of signaling, this mutation affects the ability of TrkB to promote neurite outgrowth in response to BDNF. Thus, impaired hypothalamic neurogenesis may contribute to the severe hyperphagia and obesity seen in the individual harboring the Y722C variant. The other three rare TrkB variants do not show reduced autophosphorylation or impaired downstream signaling in vitro and, as yet, it is unclear whether these variants contribute to obesity in these patients.
Introduction
The identification of single gene disorders causing severe early-onset obesity has provided insights into the physiological relevance of molecules and pathways involved in the regulation of body weight. 1 In particular, monogenic obesity syndromes arising in patients with mutations in LEPTIN, 2 LEPTIN RECEPTOR, 3 POMC, 4 PC1 5 and the 6 have demonstrated the importance of the leptin-melanocortin pathway in human energy homeostasis. Recently, it has been shown that hypothalamic neurones projecting from the arcuate nucleus to the paraventricular nucleus develop after birth, and that their development is regulated by leptin. 7 Furthermore, leptin has been shown to acutely modulate excitatory and inhibitory synaptic inputs at the level of first-order arcuate neurones. 8 Further support for the physiological relevance of hypothalamic neuronal plasticity has come from recent studies using a neuronal growth factor, ciliary neurotrophic factor (CNTF). 9 Kokoeva et al.
MELANOCORTIN 4 RECEPTOR (MC4R)
showed that in adult mice, centrally administered CNTF induced cell proliferation in feeding centers of the murine hypothalamus and elimination of cell proliferation by co-administration of a mitotic blocker was associated with a loss of the long-term, but not the short-term, effects of CNTF on body weight. 9 The neurotrophins are a family of growth factors known to be involved in the development, maintenance and function of peripheral and central neurones and may be hypothesized to play an important role in mediating neuronal plasticity in the hypothalamus. The neurotrophin receptor TrkB and its natural ligand, brain-derived neurotrophic factor (BDNF), have been implicated in the regulation of food intake and body weight. Homozygous null mutations in Ntrk2, the gene encoding TrkB, and Bdnf are lethal in rodents. 10, 11 However, TrkB hypomorphic mice expressing 24% of normal levels of TrkB are obese with increased food intake, 12 as are Bdnf heterozygous knockout mice and mice with a conditional deletion of Bdnf in the postnatal brain. 13, 14 As might be expected,
given the wide ranging effects of the neurotrophins on neuronal development, haploinsufficiency for TrkB and Bdnf in rodents is associated with complex behavioral phenotypes. Bdnf disruption has been shown to result in hyperactivity 13 and increased anxiety. 14 Mice with a forebrain-specific, postnatal deletion of Ntrk2 also demonstrate increased locomotive activity. 15 In addition, learning
and memory deficits have been demonstrated in mice with postnatal deletion of Ntrk2 in the forebrain, 16 and in
Bdnf heterozygous knockout mice, 17 phenotypes that are likely to result from impaired neuronal plasticity in the hippocampus. 16, [18] [19] [20] We have previously screened 198 subjects with severe obesity and developmental delay for sequence variants in the coding region of NTRK2. 21 We identified a de novo heterozygous missense mutation, Y722C, in a subject with severe hyperphagia and obesity, impaired learning and memory and impaired nociception. TrkB is a classical receptor tyrosine kinase, which is activated by BDNF binding, leading to receptor homodimerization, transphosphorylation and subsequent activation of the tyrosine kinase domain. Several other tyrosine residues become phosphorylated and act as docking sites for adaptor molecules such as Shc and phospholipase C (PLC)-g. Phosphorylation of these molecules results in activation of downstream signaling pathways, including mitogen-activated protein kinase (MAPK) activation and Akt phosphorylation. We performed some initial studies to see whether this mutation results in a loss of function in vitro. We showed that the Y722C NTRK2 mutation, which occurs at one of the three critical tyrosine residues in the tyrosine kinase domain, results in impaired receptor phosphorylation and signaling through MAPK.
We have now examined the in vitro consequences of the Y722C mutation in more detail and characterized the phenotype and functional consequences of three further NTRK2 variants identified in the original screening study.
Experimental subjects and procedures
Generation of stable PC12 cell lines TrkB mutant constructs were generated and transfected into PC12 (rat phaeochromocytoma) cells as previously described. 21 Using full-length human TrkB cDNA (a gift from Dr S Stamm), site-directed mutagenesis was employed to generate the mutant TrkB constructs. Full-length wild-type (WT) and mutant TrkB cDNAs were then cloned into the pBabe vector and PC12 cells stably expressing TrkB were generated by retroviral infection. Retroviruses were generated by transfecting Bosc293 packaging cells with empty pBabe vector or vector encoding WT or mutant TrkB. After 48 h, cultures were filtered, polybrene added to a concentration of 4 mg/ml and supernatants used to infect PC12 cells. After 48 h, 1 mg/ml puromycin was added to select cells. Cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 5% horse serum and incubated at 371C in humidified 5% CO 2 .
Protein analyses
On the day of assay, cells were serum-starved for 4 h, then exposed to 50 ng/ml BDNF (Sigma-Aldrich Co. Ltd, Poole, Dorset, UK) for 5 min. Protein samples were extracted by scraping cells in lysis buffer containing 1% NP-40. Samples were spun at 12 000 r.p.m. for 15 min at 41C and supernatants were kept for analysis.
Immunoprecipitation studies
Cell lysates (100 mg) were mixed with appropriate antibodies (1 ml anti-pan-Trk (1 mg/ml) (Santa Cruz Biotechnology Inc., CA, USA) or 2 ml anti-PLC-g (1.25 mg/ml) (Upstate Biotechnology, Lake Placid, NY, USA)) on a rotor overnight at 41C, then 10 ml protein G-agarose beads (50 mg/ml) was added to each sample and mixed for 2 h at 41C. The resulting immunoprecipitate was washed three times in lysis buffer, then resuspended in 25 ml of 2 Â sample buffer. Neurite outgrowth Stable PC12 cell lines were grown in 96-well plates at 5 Â 10 4 cells/ml. Next, the full medium was replaced with serum-free medium and 50 ng/ml of BDNF was added to the cultures. Cell morphology was observed 3 days after BDNF treatment under a light microscope.
Western blotting
Cell survival Stable PC12 cell lines were grown in 96-well plates at 2 Â 10 4 cells/ml. The next day (day 0), the full medium was replaced with serum-free medium supplemented with or without 50 ng/ml of BDNF. Culture medium was replaced with fresh serum-free medium supplemented with or without BDNF on days 2 and 4. Cell survival was determined at days 0 and 6 by CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA).
Results
We previously reported the Y722C TrkB variant (Figure 1) Functional characterization of human NTRK2 mutations J Gray et al in vitro, we cannot rule out a possible dominant-negative effect of the mutant receptor in a more physiological setting.
Effects of Y722C on neurite outgrowth and cell survival A major function of BDNF/TrkB signaling is to promote neuronal differentiation, neurite outgrowth, cell proliferation and survival. It is known that PC12 cells stably expressing TrkB will differentiate with extensive neurite outgrowth if treated with BDNF. 22 In order to examine the effect of Y722C on this function in vitro, we examined neurite outgrowth in PC12 cells stably expressing Y722C mutant receptor compared to WT TrkB-expressing cells. After treatment with BDNF for 3 days, neurite outgrowth was extensively established in WT TrkB-expressing cells, but severely impaired in cells expressing mutant receptor (Figure 3a ). In addition, we have utilized a cell survival assay whereby cells were treated with BDNF for 6 days and percentage survival rates calculated from cell counts on days 0 and 6. We show markedly reduced survival rates in cells expressing the mutant receptor ( Figure 3b ).
Three additional TrkB variants: I98V, P660L, T821A
Three further novel NTRK2 mutations were also previously reported, none of which were found in over 100 alleles from control subjects of the appropriate ethnic group. I98V is located in the leucine-rich repeats motif of the extracellular domain (Figure 1 ), which has been shown to affect ligand binding to TrkB. 23 P660L and T821A are both intracellularly located ( Figure 1 ): P660L in the tyrosine kinase domain, and T821A close to the PLC-g interaction site. All variants are at residues that are conserved between human, rat and mouse TrkB. All variants were found in a heterozygous form.
Clinical descriptions and genetic studies of I98V, P660L and T821A I98V was found in a 6-year-old boy of UK Caucasian origin with severe obesity (BMI s.d. 4 cells/ml with full medium in a 96-well plate. The next day (day 0), medium was replaced with serum-free medium supplemented with or without 50 ng/ml BDNF (BDNF þ or BDNFÀ). Medium was replaced again on days 2 and 4. Cell numbers were estimated on days 0 and 6. Mean and standard error from three independent experiments are shown.
Functional characterization of human NTRK2 mutations J Gray et al have severe cognitive impairment. As the probands harboring I98V, P660L and T821A all had severe obesity and developmental delay and the genetic studies proved inconclusive, we went on to characterize these three variants using in vitro assays.
Functional studies of I98V, P660L and T821A We generated PC12 cell lines stably expressing these three mutant receptors, and firstly examined autophosphorylation of these receptors after 5 min BDNF treatment. BDNFinduced receptor autophosphorylation appeared unaffected in all mutants, compared to WT TrkB-expressing cells (Figure 4) . Activation of the major downstream signaling events, MAPK activation, Akt phosphorylation and phosphorylation of PLC-g, was then analyzed from cell lysates and we again found these BDNF-induced responses to be comparable to WT in each of these mutants ( Figure 4) .
Discussion
In the current study, we have reported further functional characterization of our previously reported de novo NTRK2 variant, Y722C, associated with hyperphagia, severe obesity and a complex neurobehavioral phenotype. Here, we show severe impairment of BDNF-induced MAPK activation and PLC-g phosphorylation in Y722C TrkB stably expressing cells compared to WT TrkB-expressing cells, confirming the role of the tyrosine residue, Y722, in signaling to these pathways. Phosphorylation of Akt is also markedly reduced in the mutant receptor-expressing cell line, but to a lesser extent than MAPK and PLC-g activation, possibly reflecting the differing effects of Y722 on these distinct signaling pathways.
As a major function of BDNF/TrkB signaling is to promote neuronal differentiation, neurite outgrowth, cell proliferation and survival, we explored neurite outgrowth and cell survival rates and showed both responses to be severely impaired compared to WT TrkB. This may be explained by the observation that MAPK signaling has been shown to be important in neuronal cell differentiation and cell survival. 24 It is notable that the patient carrying the Y722C mutation in the TrkB gene was heterozygous for this variant and it is plausible that haploinsufficiency is sufficient to result in a phenotype as Bdnf heterozygous knockout mice and mice expressing 25% of normal levels of TrkB are hyperphagic and severely obese. 13, 14 However, given the fact that ligand binding initially induces TrkB dimerization and transphosphorylation of the receptor before activating downstream signaling events, 25, 26 it is possible that the Y722C mutant may be expected to have a dominant-negative effect over the WT receptor. In order to see if Y722C interferes with the WT TrkB, we transiently transfected increasing concentrations of Y722C TrkB into cells stably expressing WT receptor to see if BDNF-induced TrkB autophosphorylation was impaired in a dose-dependent manner. However, in this setting, we saw no change in cells co-transfected with mutant receptor. As we do not know about the endogenous expression levels of TrkB, a dominant-negative effect of the mutant receptor may prove difficult to show in vitro. Three additional rare variants (I98V, P660L, T821A) were identified through our screening of NTRK2. All the variants occurred in subjects with severe obesity and developmental delay. The clinical phenotype of the patients harboring the T821A variant was particularly interesting as there were marked similarities with the phenotype of the patient carrying the Y722C variant. Using PC12 cell lines stably expressing these mutants, we examined BDNF-induced receptor autophosphorylation, activation of MAPK, and PLC-g and Akt phosphorylation. However, we found these responses in the mutant receptor-expressing cells to be comparable to WT TrkB-expressing cells. Clearly, we have only looked at some of the downstream signaling molecules, reflecting the major signaling pathways for Trk receptors. Importantly, TrkB is known to interact with the p75 neurotrophins receptor, p75NTR, although the nature and physiological function of this interaction remain unclear. Additionally, a recent publication has also reported that BDNF/TrkB-evoked depolarization requires the sodium channel Na v 1.9. 27 Thus, we cannot rule out possible effects of the variants on such interactions with co-receptors, or with other adaptor molecules and it is possible that further studies will still reveal functional implications of the variants. Functional characterization of human NTRK2 mutations J Gray et al
In conclusion, the present study demonstrates impaired function of the previously reported Y722C TrkB variant on a molecular as well as a cellular level, thus providing further evidence for its pathological role in a patient with severe obesity and a complex neurobehavioral phenotype. Three further variants (I98V, P660L, T821A) were studied for their functional effects on TrkB function, but were not found to have impaired activation of the receptor tyrosine kinase, or of downstream molecules, PLC-g, MAPK and Akt, and thus we cannot conclude pathological significance of these variants in these patients.
